Immediate Impact

53 standout
Sub-graph 1 of 22

Citing Papers

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications
2024 Standout
2 intermediate papers

Works of Naoki Morimoto being referenced

Probiotics suppress nonalcoholic steatohepatitis and carcinogenesis progression in hepatocyte-specific PTEN knockout mice
2022
Transcatheter arterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable hepatocellular carcinoma (TACTICS-L) in Japan: Final analysis.
2022

Author Peers

Author Last Decade Papers Cites
Naoki Morimoto 210 139 108 193 59 681
Yixing Chen 90 78 229 210 49 735
Hisanori Shiomi 92 54 229 170 53 657
Yoshikane Yamauchi 133 39 230 448 63 807
Krishna Pillai 86 73 141 164 37 736
Vittorio Albino 210 99 196 114 43 745
Xu-Dong Qu 486 150 196 144 40 810
Yasuto Takeuchi 311 223 132 68 64 699
Wenqing Wang 56 53 199 231 70 580
Yoji Iwasaki 211 130 208 266 63 763
Daniela Brambilla 50 46 142 417 40 847

All Works

Loading papers...

Rankless by CCL
2026